Triethylamine → [5-(4-Methoxyphenyl)-1,3,4-oxadiazol-2-yl]-[3-[4-(2-oxa-7-azaspiro[4.4]nonan-7-ylmethyl)phenoxy]azetidin-1-yl]methanone

HRID 2359367노트

반응식

HRID 2359367 반응식
Cl.[CH2:2]1[C:6]2([CH2:10][CH2:9][NH:8][CH2:7]2)[CH2:5][CH2:4][O:3]1.C(N(CC)CC)C.[CH3:18][O:19][C:20]1[CH:25]=[CH:24][C:23]([C:26]2[O:30][C:29]([C:31]([N:33]3[CH2:36][CH:35]([O:37][C:38]4[CH:45]=[CH:44][C:41]([CH:42]=O)=[CH:40][CH:39]=4)[CH2:34]3)=[O:32])=[N:28][N:27]=2)=[CH:22][CH:21]=1.[Na].C([O-])(O)=O.[Na+]>ClCCl>[CH2:2]1[C:6]2([CH2:10][CH2:9][N:8]([CH2:42][C:41]3[CH:40]=[CH:39][C:38]([O:37][CH:35]4[CH2:36][N:33]([C:31]([C:29]5[O:30][C:26]([C:23]6[CH:24]=[CH:25][C:20]([O:19][CH3:18])=[CH:21][CH:22]=6)=[N:27][N:28]=5)=[O:32])[CH2:34]4)=[CH:45][CH:44]=3)[CH2:7]2)[CH2:5][CH2:4][O:3]1

참가 물질

7

반응물 5

HCID 8471TriethylamineHCID 516892Sodium BicarbonateHCID 5360545SodiumHCID 580430894-(1-(5-(4-Methoxyphenyl)-1,3,4-oxadiazole-2-carbonyl)azetidin-3-yloxy)benzaldehydeHCID 717438382-Oxa-7-azaspiro[4.4]nonane hydrochloride

생성물 1

HCID 71226697[5-(4-Methoxyphenyl)-1,3,4-oxadiazol-2-yl]-[3-[4-(2-oxa-7-azaspiro[4.4]nonan-7-ylmethyl)phenoxy]azetidin-1-yl]methanone수율 46.4%

시약·촉매·용매 1

HCID 6344Dichloromethane용매2회

실험 절차

2-Oxa-7-azaspiro[4.4]nonane HCl salt (0.057 g, 0.35 mmol) was dissolved in dichloromethane (2 ml). To the resulting solution was added triethylamine (0.052 ml, 0.38 mmol), followed by 4-(1-(5-(4-methoxyphenyl)-1,3,4-oxadiazole-2-carbonyl)azetidin-3-yloxy)benzaldehyde (0.11 g, 0.29 mmol) and sodium triacetoxyhydroborate (0.123 g, 0.58 mmol). The mixture was stirred at ambient temperature overnight. The reaction mixture was then diluted with dichloromethane (10 ml) and shaken with NaHCO3 (sat. 2 ml). The two phases were separated using a phase separator. The organic phase was evaporated. The product was purified by preparative reverse-phase HPLC at pH 10 to give 0.066 g (46%) of the desired product as a solid. 1H NMR (400 MHz, CDCl3) δ 1.92 (ddd 4H), 2.42 (d, 1H), 2.62 (dd, 3H), 3.58 (d, 3H), 3.71 (d, 1H), 3.84 (ddd, 2H), 3.92 (s, 3H), 4.35 (d, 1H), 4.67 (dd, 1H), 4.77 (d, 1H), 5.04-5.19 (m, 2H), 6.75 (d, 2H), 7.05 (d, 2H), 7.29 (d, 2H), 8.12 (d, 2H). MS (APCI+) m/z 491.3 [M+H]+, LC purity: 97%

후처리

  1. customThe two phases were separated
  2. customThe organic phase was evaporated
  3. customThe product was purified by preparative reverse-phase HPLC at pH 10

출처 및 근거

ORD 기록
ord-d1a0ea64a63b43ccb3180cc5fa7e1bb0
출처 데이터셋
uspto-grants-2014_04
특허 번호
US08685958B2

반응 노트

불러오는 중…